Ectopic expression of PTTG1/securin promotes tumorigenesis in human embryonic kidney cells

Molecular Cancer

Volumn 4, Issue , 2005, Pages

  Hamid, Tariq ^a,b   Malik, Mohammed T ^b   Kakar, Sham S ^a,b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; COMPLEMENTARY DNA; INTERLEUKIN 8; ONCOPROTEIN; PROLINE; SECURIN; UNCLASSIFIED DRUG; VASCULOTROPIN; FIBROBLAST GROWTH FACTOR 2; PITUITARY TUMOR TRANSFORMING PROTEINS; PITUITARY TUMOR-TRANSFORMING PROTEINS; TUMOR PROTEIN; VASCULOTROPIN A;

AGAR MEDIUM; ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CARCINOGENICITY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN HEK293; CELL TRANSFORMATION; CONTROLLED STUDY; DNA VECTOR; FEMALE; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN SECRETION; TUMOR PROMOTION; ANIMAL; CELL LINE; CYTOLOGY; GENETICS; KIDNEY; METABOLISM; NEOPLASM; PATHOLOGY; PRENATAL DEVELOPMENT;

RODENTIA;

ANIMALS; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; FIBROBLAST GROWTH FACTOR 2; HUMANS; INTERLEUKIN-8; KIDNEY; MICE; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASMS; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 13644256285     PISSN: 14764598     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-4598-4-3     Document Type: Article

References (54)

1. Pei L, Melmed S: Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 1997, 11:433-441.
2. Zhang X, Horwitz GA, Prezant TR, Valentini A, Nakashima M, Bronstein MD, Melmed S: Structure, expression, and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol 1999, 13:156-66.
3. Dominguez A, Ramos-Morales F, Romero F, Rios RM, Dreyfus F, Tortolero M, Pintor-Tora JA: hpttg, a human homologue of rat pttg, is overexpressed in hematopoietic neoplasms. Evidence for a transcriptional activation function of hPTTG. Oncogene 1998, 17:2187-2193.
4. Kakar SS, Jennes L: Molecular cloning and characterization of the tumor transforming gene (TUTR1): a novel gene in human tumorigenesis. Cytogenet Cell Genet 1999, 84:211-216.
5. Chen L, Puri R, Lefkowitz EJ, Kakar SS: Identification of the human pituitary tumor transforming gene (hPTTG) family: molecular structure, expression, and chromosomal localization. Gene 2000, 248:41-50.
6. Kakar SS: Assignment of the human tumor transforming gene TUTR1 to chromosome band 5q35.1 by fluorescence in situ hybridization. Cytogenet Cell Genet 1998, 83:93-5.
7. Thornton DE, Theil K, Payson R, Balcerzak SP, Chiu IM: Characterization of the 5q-breakpoint in an acute nonlymphocytic leukemia patient using pulsed-field gel electrophoresis. Am J Med Genet 1991, 41:557-65.
8. Yu R, Melmed S: Oncogene activation in pituitary tumors. Brain Pathol 2001, 11:328-41.
9. Heaney AP, Singson R, McCabe CJ, Nelson V, Nakashima M, Melmed S: Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet 2000, 355:716-719.
10. Heaney AP, Nelson V, Fernando M, Horwitz G: Transforming events in thyroid tumorigenesis and their association with follicular lesions. J Clin Endocrinol Metab 2001, 86:5025-5032.
11. Puri R, Tousson A, Chen L, Kakar SS: Molecular cloning of pituitary tumor transforming gene 1 from ovarian tumors and its expression in tumors. Cancer Lett 2001, 163:131-139.
12. Solbach C, Roller M, Fellbaum C, Nicoletti M, Kaufmann M: PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence. Breast 2004, 13: 0-81.
13. Ramaswamy S, Ross KN, Lander ES, Golub TR: A molecular signature of metastasis in primary solid tumors. Nat Genet 2003, 33:49-54.
14. Zou H, McGarry TJ, Bernal T, Kirschner MW: Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 1999, 285: 18-422.
15. Pei L: Identification of c-myc as a down-stream target for pituitary tumor-transforming gene. J Biol Chem 2001, 276: 484-8491.
16. Hamid T, Kakar SS: PTTG/securin activates expression of p53 and modulates its function. Mol Cancer 2004, 3:18.
17. Yu R, Heaney AP, Lu W, Chen J, Melmed S: Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. J Biol Chem 2000, 275:36502-36505.
18. Ishikawa H, Heaney AP, Yu R, Horwitz GA, Melmed S: Human pituitary tumor-transforming gene induces angiogenesis. J Clin Endocrinol Metab 2001, 86:867-874.
19. McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJ: Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 2002, 87:4238-4244.
20. Ruley HE: Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture. Nature 1983, 304:602-606.
21. Ravel-Chapuis P, Leprince D, Pain B, Li R, Domenget C, Stehelin D, Samarut J, Jurdic P: v-myb and v-ets cooperate for the mitogenic stimulation of primary fibroblasts by avian E26 retrovirus. J Virol 1991, 65:3928-3931.
22. Cuadrado A, Bruder JT, Heidaran MA, App H, Rapp UR, Aaronson SA: H-ras and raf-1 cooperate in transformation of NIH3T3 fibroblasts. Oncogene 1993, 8:2443-2448.
23. Stevenson M, Volsky DJ: Activated v-myc and v-ras oncogenes do not transform normal human lymphocytes. Mol Cell Biol 1986, 6:3410-3417.
24. Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P: Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 1987, 49: 65-475.
25. Langdon WY, Harris AW, Cory S: Acceleration of B-lymphoid tumorigenesis in E mu-myc transgenic mice by v-H-ras and v-raf but not v-abl. Oncogene Res 1989, 4:253-258.
26. Hahn WC, Counter CM, Lundberg AS: Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999, 400:464-468.
27. Aalinkeel R, Nair MP, Sufrin G, Mahajan SD, Chadha KC, Chawda RP, Schwartz SA: Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res 2004, 64:5311-5321.
28. Graham FL, Smiley J, Russell WC, Nairn R: Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977, 36:59-74.
29. Cheng JD, Dunbrack RL Jr, Valianou M, Rogatko A, Alpaugh RK, Weiner LM: Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res 2002, 62:4767-4772.
30. Seki Y, Suico MA, Uto A, Hisatsune A, Shuto T, Isohama Y, Kai H: The ETS transcription factor MEF is a candidate tumor suppressor gene on the X chromosome. Cancer Res 2002, 62:6579-6586.
31. Kamei D, Murakami M, Nakatani Y, Ishikawa Y, Ishii T, Kudo I: Potential role of microsomal prostaglandin E synthase-1 in tumorigenesis. J Biol Chem 2003, 278:19396-19405.
32. Hunter JA, Skelly RH, Aylwin SJ, Geddes JF, Evanson J, Besser GM, Monson JP, Burrin JM: The relationship between pituitary tumour transforming gene (PTTG) expression and in vitro hormone and vascular endothelial growth factor (VEGF) secretion from human pituitary adenomas. Eur J Endocrinol 2003, 148:203-211.
33. Singh RK, Varney ML, Bucana CD, Johansson SL: Expression of interleukin-8 in primary and metastatic malignant melanoma of the skin. Melanoma Res 1999, 9:383-387.
34. Yoneda J, Kuniyasu H, Crispens MA, Price JE, Bucana CD, Fidler IJ: Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 1998, 90:447-454.
35. Greene GF, Kitadai Y, Pettaway CA, Von Eschenbach AC, Bucana CD, Fidler IJ: Correlation of matastasis-related gene expression with metastatic poetential in human prostrate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol 1997, 150:1571-1582.
36. Zachariae CO, Thestrupp-Pedersen K, and Matsushima K: Expression and secretion of leukocute chemotatic cytokines by normal human melanocytes and melanoma cells. J Invest Dermatol 1991, 97:593-599.
37. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM: Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992, 258:1798-1801.
38. Abramov D, Erez E, Dagan O, Abramov Y, Pearl E, Veena G, Katz J, Vidne BA, Barak V: Increased levels of basic fibroblast growth factor are found in the cross-clamped heart during cardiopulmonary bypass. Can J Cardiol 2000, 16:313-318.
39. Garcia M, Samarut J: Cooperation of v-jun and v-erbB oncogenes in embryo fibroblast transformation in vitro and in vivo. J Virol 1990, 64:4684-4690.
40. Thompson TC, Southgate J, Kitchener G, Land H: Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 1989, 56:917-930.
41. Yu H, Chen JK, Feng S, Dalgarno DC, Brauer AW, Schreiber SL: Structural basis for the binding of proline-rich peptides to SH3 domains. Cell 1994, 76:933-945.
42. Chaproniere DM, McKeehan WL: Serial culture of single adult human prostatic epithelial cells in serum-free medium containing low calcium and a new growth factor from bovine brain. Cancer Res 1986, 46:819-824.
43. Maciag T, Hoover GA, Stemerman MB, Weinstein R: Serial propagation of human endothelial cells in vitro. J Cell Biol 1981, 91:420-426.
44. Allouche M, Bikfalvi A: The role of fibroblast growth factor-2 (FGF-2) in hematopoiesis. Prog Growth Factor Res 1995, 6:35-48.
45. Folkman J, Klagsbrun M: Angiogenic factors. Science 1987, 235:442-447.
46. Inger D: Extracellular matrix and cell shape: potential control point for inhibition of angiogenesis. J Cell Biochem 1991, 47:236-241.
47. Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, Manseau EJ, Van de Water L, Senger DR: Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 1991, 174: 275-1278.
48. Ke-Lin, Qu-Hong, Nagy JA, Eckelhoefer IA, Masse EM, Dvorak AM, Dvorak HF: Vascular targeting of solid and ascites tumours with antibodies to vascular endothelial growth factor. Eur J Cancer 1996, 32A:2467-2473.
49. Brekken RA, Thorpe PE: VEGF-VEGF receptor complexes as markers of tumor vascular endothelium. J Control Release 2001, 74:173-181.
50. Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002, 2:795-803.
51. Shi Q, Abbruzzese JL, Huang S, Fidler IJ, Xiong Q, Xie K: Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 1999, 5:3711-3721.
52. Venkateswaran V, Fleshner NE, Sugar LM, Klotz LH: Antioxidants block prostate cancer in lady transgenic mice. Cancer Res 2004, 64:5891-5896.
53. Kakar SS, Chen L, Puri R, Flynn SE, Jennes L: Characterization of a polyclonal antibody to human pituitary tumor transforming gene 1 (PTTG1) protein. J Histochem Cytochem 2001, 49:1537-1546.
54. Clem AL, Hamid T, Kakar SS: Characterization of the role of Sp1 and NF-Y in differential regulation of PTTG/securin expression in tumor cells. Gene 2003, 322:113-121.